DE60006692T2 - Pharmazeutische kombination von ethinylestradiol und drospirenone als empfängnisverhütendes mittel - Google Patents

Pharmazeutische kombination von ethinylestradiol und drospirenone als empfängnisverhütendes mittel Download PDF

Info

Publication number
DE60006692T2
DE60006692T2 DE60006692T DE60006692T DE60006692T2 DE 60006692 T2 DE60006692 T2 DE 60006692T2 DE 60006692 T DE60006692 T DE 60006692T DE 60006692 T DE60006692 T DE 60006692T DE 60006692 T2 DE60006692 T2 DE 60006692T2
Authority
DE
Germany
Prior art keywords
drospirenone
daily dose
ethinylestradiol
dose units
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60006692T
Other languages
German (de)
English (en)
Other versions
DE60006692D1 (de
Inventor
Wolfgang Heil
Jürgen HILMAN
Ralph Lipp
Renate Heithecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60006692(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering AG filed Critical Schering AG
Publication of DE60006692D1 publication Critical patent/DE60006692D1/de
Application granted granted Critical
Publication of DE60006692T2 publication Critical patent/DE60006692T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60006692T 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfängnisverhütendes mittel Expired - Lifetime DE60006692T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38627499A 1999-08-31 1999-08-31
US386274 1999-08-31
EP99202826 1999-08-31
EP99202826 1999-08-31
PCT/IB2000/001213 WO2001015701A1 (en) 1999-08-31 2000-08-31 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive

Publications (2)

Publication Number Publication Date
DE60006692D1 DE60006692D1 (de) 2003-12-24
DE60006692T2 true DE60006692T2 (de) 2004-09-23

Family

ID=26153359

Family Applications (5)

Application Number Title Priority Date Filing Date
DE60006692T Expired - Lifetime DE60006692T2 (de) 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfängnisverhütendes mittel
DE200912000007 Active DE122009000007I2 (de) 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel.
DE200912000006 Active DE122009000006I2 (de) 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel.
DE60041421T Expired - Lifetime DE60041421D1 (de) 1999-08-31 2000-08-31 Pharmazeutische Kombination von Ethinylestradiol und Drospirenon als empfängnisverhütendes Mittel
DE60042089T Expired - Lifetime DE60042089D1 (de) 1999-08-31 2000-08-31 Pharmazeutische Kombination von Ethinylestradiol und Drospirenon als empfängnisverhütendes Mittel

Family Applications After (4)

Application Number Title Priority Date Filing Date
DE200912000007 Active DE122009000007I2 (de) 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel.
DE200912000006 Active DE122009000006I2 (de) 1999-08-31 2000-08-31 Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel.
DE60041421T Expired - Lifetime DE60041421D1 (de) 1999-08-31 2000-08-31 Pharmazeutische Kombination von Ethinylestradiol und Drospirenon als empfängnisverhütendes Mittel
DE60042089T Expired - Lifetime DE60042089D1 (de) 1999-08-31 2000-08-31 Pharmazeutische Kombination von Ethinylestradiol und Drospirenon als empfängnisverhütendes Mittel

Country Status (26)

Country Link
EP (4) EP1380301B1 (cg-RX-API-DMAC7.html)
JP (2) JP4354667B2 (cg-RX-API-DMAC7.html)
KR (2) KR101019361B1 (cg-RX-API-DMAC7.html)
AT (3) ATE254464T1 (cg-RX-API-DMAC7.html)
AU (4) AU780330B2 (cg-RX-API-DMAC7.html)
BG (1) BG66114B1 (cg-RX-API-DMAC7.html)
BR (1) BR0014159A (cg-RX-API-DMAC7.html)
CY (3) CY1108990T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ300514B6 (cg-RX-API-DMAC7.html)
DE (5) DE60006692T2 (cg-RX-API-DMAC7.html)
DK (3) DK1380301T3 (cg-RX-API-DMAC7.html)
EE (1) EE05128B1 (cg-RX-API-DMAC7.html)
ES (3) ES2319750T3 (cg-RX-API-DMAC7.html)
HK (1) HK1047247B (cg-RX-API-DMAC7.html)
HR (1) HRP20070188B1 (cg-RX-API-DMAC7.html)
HU (1) HU227207B1 (cg-RX-API-DMAC7.html)
IL (1) IL148339A0 (cg-RX-API-DMAC7.html)
ME (2) ME00329B (cg-RX-API-DMAC7.html)
NO (1) NO326860B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ517845A (cg-RX-API-DMAC7.html)
PL (1) PL199028B1 (cg-RX-API-DMAC7.html)
PT (3) PT1380301E (cg-RX-API-DMAC7.html)
RS (3) RS50262B2 (cg-RX-API-DMAC7.html)
SI (3) SI1214076T1 (cg-RX-API-DMAC7.html)
TW (1) TWI276436B (cg-RX-API-DMAC7.html)
WO (1) WO2001015701A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1380301T3 (da) * 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
AU2001225413B2 (en) * 2000-01-18 2005-06-23 Bayer Schering Pharma Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1353699B1 (en) * 2000-12-20 2012-02-01 Bayer Pharma Aktiengesellschaft Beta-cyclodextrin-drospirenone inclusion complexes
BR0309780A (pt) * 2002-04-26 2005-03-22 Schering Aktiengellschaft Tratamento da hipertensão em mulheres recebendo terapia de reposição hormonal
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
DE602005014227D1 (de) * 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
WO2006102750A1 (en) * 2005-03-30 2006-10-05 Genpharm Inc. Combined-step process for pharmaceutical compositions
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP1900359A1 (en) * 2006-09-16 2008-03-19 KAIROSmed GmbH Oral modified release formulations containing drospirenon and 8-prenylnaringenin for use in female contraception
US20100086599A1 (en) * 2006-09-16 2010-04-08 Kairosmed Gmbh Oral modified release formulations
UY31010A1 (es) * 2007-04-05 2008-11-28 Bayer Schering Pharma Ag Nuevo régimen de drospirenona/17b-estradiol, producto farmacéutico combinado y conjunto de elementos (kit) para su aplicacion
HUP0700826A3 (en) 2007-12-20 2010-03-29 Richter Gedeon Nyrt Coated tablet containing drospirenone and process for producing the same
TW200946542A (en) * 2008-03-10 2009-11-16 Vladimir Hanes New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2009112231A2 (en) * 2008-03-10 2009-09-17 Schuermann Rolf New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
CA2752805A1 (en) * 2009-02-18 2010-08-26 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
KR20130097073A (ko) * 2010-04-15 2013-09-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 초저-용량의 hrt용 고체 경구 투여 형태
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
IT202100008834A1 (it) 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
WO2023152658A1 (en) 2022-02-10 2023-08-17 Lupin Limited Slow release drospirenone tablet composition
EP4486311A1 (en) * 2022-03-01 2025-01-08 Chemo Research, S.L. Chewable oral contraceptive

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3051168C2 (de) * 1979-01-24 1998-08-27 Minnesota Mining & Mfg Mono- bzw. Polycarbonsäureester oder deren Gemische oder Ester bzw. deren Gemische aus Isocyanaten und fluor- bzw. chlorhaltigen aliphatischen Alkoholen
DE3051166C2 (en) 1980-06-11 1990-10-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Compsns. for contraception or treatment of gynaecological disorders
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
DE3682130D1 (de) * 1985-07-15 1991-11-28 Japan Res Dev Corp Verfahren zur herstellung von ultrafeinen organischen verbindungen.
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
ZA939566B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for dry blend compression od medicaments.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
EP0782449B1 (en) * 1994-09-22 2003-04-09 Akzo Nobel N.V. Process of making dosage units by wet granulation
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
AU713016B2 (en) * 1996-07-26 1999-11-18 Wyeth Oral contraceptive
PT956024E (pt) * 1996-07-26 2004-10-29 Wyeth Corp Metodo contraceptivo oral monofasico e estojo ("kit") compreendendo uma combinacao de uma progestina e estrogenio
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DK1380301T3 (da) * 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
AU2001225413B2 (en) * 2000-01-18 2005-06-23 Bayer Schering Pharma Aktiengesellschaft Drospirenone for hormone replacement therapy

Also Published As

Publication number Publication date
DE60041421D1 (de) 2009-03-05
KR100857344B1 (ko) 2008-09-05
HK1047247B (en) 2004-07-23
CY1109252T1 (el) 2014-07-02
BR0014159A (pt) 2002-05-07
HU227207B1 (en) 2010-11-29
EE200200110A (et) 2003-06-16
DK1380301T3 (da) 2009-04-20
DE122009000007I1 (de) 2009-05-07
HUP0202500A2 (en) 2002-10-28
JP2003508441A (ja) 2003-03-04
CY2009015I1 (el) 2014-02-12
KR20020040798A (ko) 2002-05-30
PT1598069E (pt) 2009-07-20
TWI276436B (en) 2007-03-21
YU14502A (sh) 2006-01-16
JP2009143959A (ja) 2009-07-02
EP1598069A3 (en) 2006-04-05
DE60006692D1 (de) 2003-12-24
JP4354667B2 (ja) 2009-10-28
AU2005202046B2 (en) 2008-11-20
HRP20070188A2 (en) 2007-07-31
DK1598069T3 (da) 2009-07-06
RS50262B (sr) 2009-07-15
ATE429231T1 (de) 2009-05-15
RS50262B2 (sr) 2018-10-31
PT1380301E (pt) 2009-03-30
CY1108990T1 (el) 2014-02-12
CZ300514B6 (cs) 2009-06-03
EP1598069A2 (en) 2005-11-23
KR20070067248A (ko) 2007-06-27
EP1214076B1 (en) 2003-11-19
PL199028B1 (pl) 2008-08-29
DE122009000007I2 (de) 2011-07-21
HK1082432A1 (en) 2006-06-09
DE122009000006I2 (de) 2012-03-22
DE122009000006I1 (de) 2009-05-07
IL148339A0 (en) 2002-09-12
EP1598069B1 (en) 2009-04-22
NO326860B1 (no) 2009-03-02
SI1380301T1 (sl) 2009-06-30
ME00329B (me) 2011-05-10
ATE420648T1 (de) 2009-01-15
ATE254464T1 (de) 2003-12-15
AU2009200247B2 (en) 2010-07-01
AU780330B2 (en) 2005-03-17
NZ517845A (en) 2004-12-24
PL354406A1 (pl) 2004-01-12
HK1061968A1 (en) 2004-10-15
PT1214076E (pt) 2004-04-30
RS20090134A (sr) 2009-11-10
HK1047247A1 (en) 2003-02-14
DK1214076T3 (da) 2004-02-23
HRP20070188B1 (hr) 2015-06-19
EP1214076A1 (en) 2002-06-19
HUP0202500A3 (en) 2004-04-28
EP1380301A1 (en) 2004-01-14
BG66114B1 (bg) 2011-05-31
AU2010226924A1 (en) 2010-10-28
AU6589500A (en) 2001-03-26
NO20020801D0 (no) 2002-02-19
NO20020801L (no) 2002-04-26
KR101019361B1 (ko) 2011-03-07
EP2044941A1 (en) 2009-04-08
SI1214076T1 (en) 2004-06-30
ES2325589T3 (es) 2009-09-09
EP1380301B1 (en) 2009-01-14
CY2009015I2 (el) 2014-02-12
EE05128B1 (et) 2009-02-16
AU2009200247A1 (en) 2009-02-19
ES2211580T3 (es) 2004-07-16
ES2319750T3 (es) 2009-05-12
MEP36008A (hr) 2011-02-10
SI1598069T1 (sl) 2009-10-31
CZ2002615A3 (cs) 2002-08-14
WO2001015701A1 (en) 2001-03-08
AU2005202046B9 (en) 2008-12-11
DE60042089D1 (de) 2009-06-04
AU2005202046A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
DE60113809T2 (de) Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie
KR100857344B1 (ko) 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합
US6787531B1 (en) Pharmaceutical composition for use as a contraceptive
RU2482853C2 (ru) Фармацевтическая композиция, способ ее получения и многофазный фармацевтический препарат для ингибирования овуляции у млекопитающего
DE4229820C2 (de) Pharmazeutische Zubereitung auf Gestagen-Basis
EP1761242A2 (de) Filmförmiges, oral zu verabreichendes arzneimittel, enthaltend estriol
DE102008033254B4 (de) Verfahren zur Herstellung eines einphasischen pharmazeutischen Präparates zur oralen Therapie der Regulierung des Blutdruckes
AU2014227490A1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
ZA200404083B (en) Pharmaceutical combination of ethinylestradiol anddrospirenone for use as a contraceptive.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE

8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE

V448 Application of spc

Free format text: PRODUCT NAME: YAZ 0,02 MG/3 MG FILMTABLETTEN; REGISTRATION NO/DATE: 71898.00.00, 20080716

Spc suppl protection certif: 12 2009 000 006

Filing date: 20090116

Free format text: PRODUCT NAME: ETHINYLESTRADIOL/DROSPIRENON 24+4 0,02MG/3 MG FILMTABLETTEN; REGISTRATION NO/DATE: 71899.00.00, 20080716

Spc suppl protection certif: 12 2009 000 007

Filing date: 20090116

R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: YAZ 0,02 MG/3 MG FILMTABLETTEN; AUTHORISATION NO/DATE: 71898.00.00 20080716; RVG 33842 20070629

Spc suppl protection certif: 122009000006

Free format text: PRODUCT NAME: ETHINYLESTRADIOL/DROSPIRENON 24+4 0,02MG/3 MG FILMTABLETTEN; AUTHORISATION NO/DATE: 71899.00.00 20080716; RVG 33842 20070629

Spc suppl protection certif: 122009000007

V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: YAZ 0,02 MG/3 MG FILMTABLETTEN; REGISTRATION NO/DATE: 71898.00.00, 20080716

Spc suppl protection certif: 12 2009 000 006

Filing date: 20090116

R067 Examining division decision granting supplementary protection certificate

Free format text: PRODUCT NAME: ETHINYLESTRADIOL/DROSPIRENON 24+4 0,02MG/3 MG FILMTABLETTEN; AUTHORISATION NO/DATE: 71899.00.00 20080716; RVG 33842 20070629

Spc suppl protection certif: 122009000007

R067 Examining division decision granting supplementary protection certificate

Free format text: PRODUCT NAME: YAZ 0,02 MG/3 MG FILMTABLETTEN; AUTHORISATION NO/DATE: 71898.00.00 20080716; RVG 33842 20070629

Spc suppl protection certif: 122009000006

V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: ETHINYLESTRADIOL/DROSPIRENON 24+4 0,02MG/3 MG FILMTABLETTEN; REGISTRATION NO/DATE: 71899.00.00, 20080716

Spc suppl protection certif: 12 2009 000 007

Filing date: 20090116

R069 Supplementary protection certificate granted

Free format text: PRODUCT NAME: ETHINYLESTRADIOL/DROSPIRENON 24+4 0,02MG/3 MG FILMTABLETTEN; AUTHORISATION NO/DATE: 71899.00.00 20080716; RVG 33842 20070629

Spc suppl protection certif: 122009000007

V457 Spc granted

Free format text: PRODUCT NAME: ETHINYLESTRADIOL/DROSPIRENON 24+4 0,02MG/3 MG FILMTABLETTEN; REGISTRATION NO/DATE: 71899.00.00, 20080716

Spc suppl protection certif: 12 2009 000 007

Filing date: 20090116

R069 Supplementary protection certificate granted

Free format text: PRODUCT NAME: YAZ 0,02 MG/3 MG FILMTABLETTEN; AUTHORISATION NO/DATE: 71898.00.00 20080716; RVG 33842 20070629

Spc suppl protection certif: 122009000006

V457 Spc granted

Free format text: PRODUCT NAME: YAZ 0,02 MG/3 MG FILMTABLETTEN; REGISTRATION NO/DATE: 71898.00.00, 20080716

Spc suppl protection certif: 12 2009 000 006

Filing date: 20090116

SP81

Free format text: PREVIOUS APPLICANT: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE; PRODUCT NAME: YAZ 0,02 MG/3 MG FILMTABLETTEN; AUTHORISATION NO/DATE: 71898.00.00 20080716; RVG 33842 20070629

Spc suppl protection certif: 122009000006

Free format text: PREVIOUS APPLICANT: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE; PRODUCT NAME: ETHINYLESTRADIOL/DROSPIRENON 24+4 0,02MG/3 MG FILMTABLETTEN; AUTHORISATION NO/DATE: 71899.00.00 20080716; RVG 33842 20070629

Spc suppl protection certif: 122009000007

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE

Free format text: PREVIOUS APPLICANT: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE; PRODUCT NAME: YAZ 0,02 MG/3 MG FILMTABLETTEN; AUTHORISATION NO/DATE: 71898.00.00 20080716; RVG 33842 20070629

Spc suppl protection certif: 122009000006

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE

Free format text: PREVIOUS APPLICANT: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE; PRODUCT NAME: ETHINYLESTRADIOL/DROSPIRENON 24+4 0,02MG/3 MG FILMTABLETTEN; AUTHORISATION NO/DATE: 71899.00.00 20080716; RVG 33842 20070629

Spc suppl protection certif: 122009000007